The U.S. Food and Drug Administration said on Monday it will not take action against compounding pharmacies making copies of ...

In a statement, Trotter described his experience as a child with older relatives who struggled with Type 2 diabetes. Trotter ...

Novo Nordisk (NYSE: NVO) shareholders know all about the ups and downs of pharmaceutical stock investing. From the beginning ...

Fact checked by Nick Blackmer Novo Nordisk launched a direct-to-consumer program last week to sell Wegovy at a reduced price ...

Novo Nordisk said it will offer all doses of Wegovy for $499 a month to patients paying cash, a bid to reach consumers who ...

Novo Nordisk (NVO), the company behind popular diabetes and weight loss medications Ozempic and Wegovy, warned that President ...

Despite the current downward trend of NVO, it is a good stock to retain in one's portfolio for long-term gains due to strong ...

Novo Nordisk is cutting the cost of its blockbuster ... do not have coverage can access all dose strengths of Wegovy, the brand name for semaglutide, for $499 per month. This includes 0.25 mg ...

Danish drugmaker Novo Nordisk said Wednesday that it will drop prices 23% for all doses of Wegovy. The new monthly price of ...

In addition to competing with compounding pharmacies, Novo Nordisk must compete with tirzepatide from Eli Lilly (NYSE: LLY). The FDA approved Lilly's GLP-1 drug, tirzepatide, under the brand name ...